🔗 Share this article

Elected officials have issued warnings that the United Kingdom's series of deals with Washington are "built on sand." This comes after revelations that a much-touted deal on medicines, which promises zero tariffs in exchange for the NHS facing higher prices, lacks any detailed agreement beyond vague headline terms published in government press releases.

Lacking Legal Footing

The arrangement concerning medicines, hailed as a "significant" achievement, remains an "statement of intent" without formal ratification. Observers point out that the official announcements from the UK and US governments frame the deal in sharply different terms. The British version emphasizes securing "zero per cent tariffs" as a unique achievement, while the American announcement concentrates on the commitment for the NHS to pay higher prices for new medications.

"We face a genuine possibility that the UK government has made commitments to increase medicine costs in return for only a pledge from President Trump," commented David Henig, a trade policy analyst. "We know he has form for not keeping promises."

Broader Instability and a Paused Tech Deal

Concerns have been intensified by Washington's move to suspend the £31bn "tech prosperity deal", which was previously described as "a transformative pact" in the bilateral relationship. The US cited a insufficient movement from the UK on addressing wider trade issues as the reason for the pause.

In a separate development, concessions secured for British farmers as part of an initial accord have yet to be formally approved by the US, despite a looming January deadline. "We have been informed that that the US has failed to approve the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

In confidential discussions, ministers have expressed concerns that the government's agreements with the US are unstable and unpredictable. One minister described the series of agreements as "built on sand," while another described the situation as the "prevailing condition" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, chair of the health select committee, argued: "What is even more astonishing than Trump's temper tantrums is the UK government's credulous faith that his administration is a reliable partner. The NHS is of vital importance."

A Mixed Picture of Success and Setback

Ministry sources have attempted to minimize the risk of the US reneging on the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been pushing for the agreement, desiring stability on imports and pricing, making it more concrete than the paused tech deal.

Officials acknowledge that unpredictability is part and parcel of dealing with the current US leadership. However, they contend that the UK has secured concrete outcomes for businesses, such as reduced duties on automobiles compared to other nations. "Our achievement of 25% steel tariffs, which is lower than the rate for the rest of the world, is a solid gain," one official said.

However, problems have emerged in enacting the broader trade deal. Promised access for British beef have yet to be finalized, and the commitment to "reduce steel tariffs to zero" has is still pending, with tariffs fixed at 25%.

Looking ahead, the two sides have scheduled to restart talks on the paused tech prosperity deal in January, following what were described as "very positive" meetings between UK and US officials in Washington.